Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-01-18
2011-01-18
Vivlemore, Tracy (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C435S320100, C514S04400A
Reexamination Certificate
active
07872117
ABSTRACT:
Suppression of the Hepatocyte growth factor/scatter factor (HGF/SF)-Met signaling pathway by targeting the Met protein tyrosine kinase was tested as strategy for suppressing tumor growth. Using RNA interference (RNAi) technology and adenoviruses carrying siRNA (Ad Met siRNA) target sequences dramatically reduced Met expression in mouse, dog and human tumor cells. Met was suppressed using Ad Met siRNA in mouse mammary tumor (DA3) cells and Met-transformed (NIH3T3 (M114) cells as well as human prostate cancer, sarcoma, glioblastoma, gastric and ovarian cancer cells. Furthermore, the Ad Met siRNA infection reversed transformed cell morphology. Ad Met siRNA killed cancer cells by inducing apoptosis. RNAi targeting Met suppressed HGF/SF-mediated scattering as well as ligand-mediated invasion activity and growth of tumor cells. Met siRNA infection also abrogated downstream Met signaling to molecules such as Akt and p44/42 MAPK. Importantly, the Met siRNA triggered apoptosis was correlated to suppressed tumorigenicity in vivo. Intro-tumoral infection with c-met siRNA adenovirus vectors produced significant reduction in tumor growth. Thus Met RNAi is an effective weapon for targeting Met expression and for treating c-Met+cancers.
REFERENCES:
patent: 5716832 (1998-02-01), Barber et al.
patent: 5795715 (1998-08-01), Livache et al.
patent: 5932210 (1999-08-01), Gregory et al.
patent: 2003/0180756 (2003-09-01), Shi et al.
patent: 2004/0162255 (2004-08-01), Kaemmerer
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2004/0265230 (2004-12-01), Martinez et al.
patent: 1243596 (2002-09-01), None
Abounader et al. (2002) FASEB J. 16(1):108-110.
Elbashir et al. et al. (2002) Methods 26:199-213.
Good et al. (1997) “Expression of small, therapeutic RNAs in human cell nuclei” Gene Therapy 4:45-54.
Birchmeier C, et al. Met, Metastasis, Motility and More. Nat Rev Mol Cell Biol, No. 4: 915-925 (Dec. 2003).
Cotella N, et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J. vol. 17: pp. 1162-1164 (Jun. 2003).
Fire A, et al. Potent and specific genetic interference by double-stranded RNA inCaenorhabditis elegans. Nature (London) vol. 391: pp. 806-811 (Feb. 1998).
Gherardi E, et al. Hepatocyte Growth Factor-Scatter Factor: Mitogen, Motogen, and Met. Cancer Cells (Cold Spring Harbor) vol. 3: pp. 227-232 (Jun. 1991).
Herynk M, et al. Down-Regulation of c-Met Inhibits Growth in the Liver of Human Colorectal Carcinoma Cells. Cancer Research vol. 63: pp. 2990-2996 (Jun. 1, 2003).
Lin S, et al. D-RNAi (Messenger RNA-antisense DNA Interference) as a Novel Defense System Against Cancer and Viral Infections. Curr Cancer Drug Targets vol. 1: pp. 241-247 (2001).
Maemondo M, et al. Targeting Angiogenesis and HGF Function Using an Adenoviral Vector Expressing the HGF Antagonist NK4 for Cancer Therapy. Molecular Therapy vol. 5 (No. 2): pp. 177-185 (Feb. 2002).
Paddison P, et al. RNA interference: the new somatic cell genetics? Cancer Cell vol. 2: pp. 17-23 (Jul. 2002).
Rong S, et al. Tumorigenicity of the met Proto-Oncogene and the Gene for Hepatocyte Growth Factor. Mol Cell Biology vol. 12 (No. 11): pp. 5152-5158 (Nov. 1992).
Shinomiya N, et al. Suppression of Met Expression: A Possible Cancer Treatment. Clinical Cancer Research vol. 9: pp. 5085-5090 (Nov. 1, 2003).
Sui G, et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci vol. 99 (No. 8): pp. 5515-5520 (Apr. 16, 2002).
Tuschl T, et al. Targeted mRNA degradation by double-stranded RNA in vitro. Genes & Development vol. 13: pp. 3191-3197 (Oct. 1999).
Abounader, Roger et al., “In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis,” The FASEB Journal, vol. 16, Jan. 2002, pp. 108-110.
Ma, Patrick C. et al., “c-Met: Structure, functions and potential for therapeutic inhibition,” Cancer and Metastasis Reviews, vol. 22, Dec. 2003, pp. 309-325.
Shinomiya, Nariyoshi et al., “RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival,” Cancer Research, vol. 64, Nov. 1, 2004, pp. 7962-7970.
Shinomiya Nariyoshi
Vande Woude George F.
Price Heneveld Cooper DeWitt & Litton LLP
Van Andel Research Institute
Vivlemore Tracy
LandOfFree
c-met siRNA adenovirus vectors inhibit cancer cell growth,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with c-met siRNA adenovirus vectors inhibit cancer cell growth,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and c-met siRNA adenovirus vectors inhibit cancer cell growth,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2681723